NKGen Biotech Company Overview
About NKGen Biotech
NKGen Biotech (NASDAQ:NKGN) specializes in the innovative field of biotechnology, focusing on developing cutting-edge therapeutic solutions with a commitment to improving patient outcomes in various medical conditions. The core of its operations revolves around harnessing the power of advanced scientific research to create and develop novel treatments that address unmet medical needs. Among its diverse projects, NKGen Biotech places particular emphasis on immunotherapy and cell therapy technologies, aiming to lead the way in transforming how diseases are treated. The company's objectives are centered on advancing its portfolio of therapeutic candidates through clinical trials, securing regulatory approvals, and establishing strong partnerships within the healthcare sector to ensure their groundbreaking therapies reach patients worldwide.
Snapshot
Operations
Products and/or services of NKGen Biotech
- SNK01, an autologous natural killer cell therapy aimed at treating various types of cancer.
- NK cell manufacturing technology, enabling scalable production of high-purity, activated NK cells for therapeutic use.
- Mechanism enhancement research, dedicated to improving NK cell persistence and cytotoxicity against tumor cells.
- Collaborative studies with leading pharmaceutical companies to explore combination therapies involving NK cells.
- Advancement of NK cell storage solutions, ensuring longer shelf life and stability for clinical applications.
- Development of proprietary assays to measure NK cell activity and efficacy in real-time.
NKGen Biotech executive team
- Dr. Paul Y. Song M.D.CEO & Chairman
- Dr. Yong Man Kim Ph.D.Chief Scientific Officer
- Mr. James A. GrafInterim Chief Financial Officer
- Ms. Yoonmi KangSVP of Technical Ops & Development
- Ms. Irene ChangSVP, HR & Corporate Culture
- Ms. Denise A. Chua CLS, MBA, MT (ASCP)SVP of Corporate Affairs
- Mr. Ryan Park C.F.A.EVP of Financial Planning & Analysis and Corporate Strategy